lapatinib has been researched along with epirubicin in 8 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (epirubicin) | Trials (epirubicin) | Recent Studies (post-2010) (epirubicin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 5,453 | 1,838 | 1,570 |
| Protein | Taxonomy | lapatinib (IC50) | epirubicin (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.75 | ||
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 5.181 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Artioli, F; Bagnalasta, M; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; D'Amico, R; Frassoldati, A; Generali, DG; Giardina, G; Guarneri, V; Marini, L; Musolino, A; Orlando, L; Piacentini, F; Ravaioli, A; Sarti, S; Serra, P; Untch, M | 1 |
| Alba, E; Albanell, J; Barnadas, A; Burgués, O; Caballero, R; Calvo, L; Cámara, MC; Carrasco, E; de la Haba, J; Lluch, A; Porras, I; Ramos, M; Rojo, F; Sánchez-Rovira, P; Tibau, A | 1 |
| Bodmer, A; Bonnefoi, H; Brain, E; Cameron, D; Chakiba, C; Jacot, W; Jerusalem, G; Matos, E; Messina, CG; Moldovan, C; Petit, T; Quenel-Tueux, N; Saghatchian, M; Slaets, L; Tredan, O; Venat-Bouvet, L; Vuylsteke, P; Zaman, K | 1 |
| Blohmer, JU; Eggemann, H; Fasching, PA; Fehm, T; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schem, C; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Atasoy, A; Caballero, C; Freire, J; John, JMM; Lang, I; Lutz, MP; Maderer, A; Mauer, ME; Moehler, M; Roth, A; Schad, A; Thomaidis, T; Van Cutsem, E | 1 |
1 review(s) available for lapatinib and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for lapatinib and epirubicin
| Article | Year |
|---|---|
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome | 2018 |
2 other study(ies) available for lapatinib and epirubicin
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |